Inactivated respiratory syncytial viral vaccines
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Aug 1, 2006
Issued Date -
N/A
app pub date -
Aug 4, 1994
filing date -
Aug 6, 1993
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
An immunogenic composition capable of producing a respiratory syncytial (RS) virus specific immune response in a host immunized therewith comprises purified, inactivated RS virus which is substantially free from cellular and serum components and which is non-infectious, non-immunopotentiating, immunogenic and protective. The virus is grown on a vaccine quality cell line and harvested virus is purified under non-denaturing conditions to be substantially free from cellular and serum components. The purified RS virus is inactivated using .beta.-propiolactone, a non-ionic detergent, particularly n-octyl-.alpha.-D-glucopyranoside and n-octyl-.beta.-D-glucopyranoside, or ascorbic acid. The immunogenic composition may be formulated as a vaccine for in vivo administration to a human host. The immunogenic composition also may be used in diagnostic applications.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully